Market Access Makary: Drugs don’t have to take 10 years to get to market FDA Commissioner Dr Martin Makary took the stage at BIO 2025 to detail the way he and his team have been challenging “deeply held assumptions”.
Market Access Political uncertainties, tariffs, funding crunch? LSX World ... The weather was hot in London for this year’s LSX World Congress – but what was the atmosphere like at Europe’s leading partnering, strategy, and investment event?
Market Access Is money the only metric that really matters in UK’s VPAG? I... The UK’s Voluntary Scheme that covers pricing, access, and growth of branded medicines has been generating a lot of attention lately.
Market Access VCs upbeat about European life sciences market, despite unce... It has been a curious start to the year for pharma and biotech investment.
Market Access EAPs: Market access outside of the US and Western Europe In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals about early access programmes.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
R&D Precision, speed, impact: Evolving mass spectrometry for med... MOBILion's Melissa Sherman explores the evolving role of mass spectrometry in drug discovery, complex molecule analysis, and medical research.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face